

Neurofibromatosis

[View the current Neurofibromatosis InDepth page on BioPortfolio.com \(PDF\)](#)

(<http://www.bioportfolio.com/indepth/Neurofibromatosis.html>) - Regularly Updated.

Neurofibromatosis is an autosomal dominant genetic disorder. It encompasses a set of distinct genetic disorders that cause tumors to grow along types of nerves and, in addition, can affect the development of non-nervous tissues such as bones and skin. The tumors can grow anywhere on or in the body. Incidence is 1:3,000. ([From the Wikipedia article Neurofibromatosis.](#))



Recent Publications on Neurofibromatosis:

- [Myelin protein zero Val102fs mutation manifesting with isolated spinal root hypertrophy.](#)
The Val102fs mutation of the myelin protein zero gene (MPZ) has been... 13th November, 2009
Department of Neurology San Martino's Hospital, Belluno, Italy.- *Neuromuscul Disord.* 2009 Nov 9. ([DOI Direct Link](#))
- [\[Anterior release combined with posterior correction for the treatment of severe scoliosis\]](#)
OBJECTIVE: To evaluate the clinical results of anterior spinal release... 12th November, 2009
Department of Orthopaedics, the 2nd People's Hospital of Shanxi, Taiyuan- *Zhongguo Gu Shang.* 2009 Oct;22(10):781-2.
- [Inhibition of Eyes Absent Homolog 4 expression induces malignant peripheral nerve sheath tumor necrosis.](#)
Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive sarcomas... 11th November, 2009
Department of Pediatrics, Division of Experimental Hematology and Cancer- *Oncogene.* 2009 Nov 9. ([DOI Direct Link](#))
- [Biological basis for the use of autologous bone marrow stromal cells in the treatment of congenital pseudarthrosis of the tibia.](#)
The study was designed to establish the biological basis for the use of... 11th November, 2009
Laboratory for Orthopaedic Pathophysiology and Regenerative Medicine,- *Bone.* 2009 Nov 6. ([DOI Direct Link](#))
- [Speech disorders in neurofibromatosis type 1: a sample survey.](#)
Background: Neurofibromatosis type 1 (NF1) is an autosomal-dominant... 11th November, 2009
Department of Otorhinolaryngology, Ghent University, Ghent, Belgium.- *Int J Lang Commun Disord.* 2009 Nov 10.
- [\[Pheochromocytoma: diagnosis and treatment\]](#)
Pheochromocytoma (phea) is adrenal or less frequently extraadrenal tumour... 11th November, 2009
Centrum pro hypertenzi - III. interni klinika 1. LF UK a VFN, U Nemocnice- Cas Lek Cesk. 2009;148(8):365-9.
- [The neurofibromatoses. Part 2: NF2 and schwannomatosis.](#)
The neurofibromatoses, including neurofibromatosis 1 (NF1),... 10th November, 2009
Department of Neurology, University of Washington, Seattle, WA, USA.- *Rev Neurol Dis.* 2009

Summer;6(3):E81-6.

- [Genome-wide transcriptome analyses reveal p53 inactivation mediated loss of miR-34a expression in malignant peripheral nerve sheath tumours.](#)
*Malignant peripheral nerve sheath tumours (MPNSTs) are aggressive soft...*6th November, 2009
Department of Laboratory Medicine and Pathology, University of Minnesota,- J Pathol. 2009 Oct 1. ([DOI Direct Link](#))
- [Neurofibromatosis type 1 in an adult diagnosed by a pulmonologist.](#)
*Neurofibromatosis type 1 (NF1), referred to as von Recklinghausen's...*6th November, 2009
- Pneumonol Alergol Pol. 2009;77(5):474-8.
- [Type 1 Neurofibromatosis and Arnold-Chiari Malformation.](#)
*Neurofibromatosis type 1 (NF1), referred to as von Recklinghausen's...*6th November, 2009
Seccion de Neurologia. Complejo Hospitalario Arquitecto Marcide-Novoa- Actas Dermosifiliogr. 2009 Nov;100(9):820-822.
- [Cochlear Implantation in Neurofibromatosis Type 2 After Radiation Therapy.](#)
*OBJECTIVE:: To investigate the results of cochlear implantation in...*6th November, 2009
Royal Victorian Eye and Ear Hospital, Melbourne, Victoria, Australia.- Otol Neurotol. 2009 Oct 31. ([DOI Direct Link](#))
- [\[Carcinoid of the minor duodenalpapilla associated with multiple jejunal leiomyomas in type 1 neurofibromatosis\]](#)
*Duodenal endocrine tumors are rare and represent 2% of all...*5th November, 2009
Catedra Chirurgie nr. 1 N. Anestiadi si Laboratorul de Chirurgie- Chirurgia (Bucur). 2009 Jul-Aug;104(4):491-4.
- [FRET Analysis of Merlin Conformational Changes.](#)
*Neurofibromatosis Type 2 is an inherited autosomal disorder caused by...*4th November, 2009
Departments of Cancer & Cell Biology and Molecular Genetics, Biochemistry- Mol Cell Biol. 2009 Nov 2. ([DOI Direct Link](#))
- [Multiple gastrointestinal stromal tumors in neurofibromatosis type 1: report of a case.](#)
*This report presents a case of multiple gastrointestinal stromal tumors...*3rd November, 2009
Department of Gastroenterological Surgery, Kumamoto University, Kumamoto- Surg Today. 2009;39(11):979-83. Epub 2009 Nov 1. ([DOI Direct Link](#))
- [Stroke and cerebrovascular disorders.](#)
*PURPOSE OF REVIEW: Stroke and cerebrovascular disorders in childhood are a...*3rd November, 2009
aDivision of Neurology, Hospital for Sick Children, Toronto, Ontario,- Curr Opin Pediatr. 2009 Oct 29. ([DOI Direct Link](#))

BioNews Results for Neurofibromatosis

- [Screening MRIs Find Clinically Significant Pathology in Children With Neurofibromatosis 1](#)
Medscape: Nov 12 2009 4:39PM Matching: neurofibromatosis
- [Vascular Endothelial Cell Function Is Impaired in Neurofibromatosis 1 Patients](#)
Medscape: Nov 2 2009 4:31PM Matching: neurofibromatosis
- [Gene Alterations Replicate Neurofibromatosis in Mice](#)
Modern Medicine: Oct 30 2009 12:41AM Matching: neurofibromatosis
- [Mutation linked to pediatric brain tumor may pave way for targeted treatment](#)
Washington University in St. Louis: Oct 29 2009 10:24PM Matching: neurofibromatosis
- [Hearing Improvement after Bevacizumab for Neurofibromatosis Type 2](#)
New England Journal of Medicine: Oct 28 2009 10:27PM Matching: neurofibromatosis

Neurofibromatosis Clinical Trials:



- [Trial to Evaluate the Safety of Lovastatin in Individuals With Neurofibromatosis Type I \(NF1\)](#)

Neurofibromatosis Patents:



- 7560253- [HLS-5 tumor suppressor factor](#)
- 7569384- [Albumin fusion proteins](#)
- 7572442- [Selected antibody compositions for binding to aminophospholipids](#)
- 7572448- [Combined cancer treatment methods using selected antibodies to aminophospholipids](#)
- 7572596- [Modulation of the neuroendocrine system as a therapy for motor neuron disease](#)
- 7572781- [Prodrugs for use as ophthalmic agents](#)
- 7572899- [Compositions and methods for increasing bone mineralization](#)
- 7576072- [Heterocyclic inhibitors of MEK and methods of use thereof](#)
- 7578999- [Antibodies specific for sclerostin](#)
- 7579473- [c-Met modulators and methods of use](#)
- 7582289- [Viruses for the treatment of cellular proliferative disorders](#)
- 7569054- [Tubular member having a passage and opposed bone contacting extensions](#)
- 7566729- [Modifying pirfenidone treatment for patients with atypical liver function](#)
- 7560275- [Compositions and methods for generating skin](#)
- 7560280- [Human cord blood derived unrestricted somatic stem cells \(USSC\)](#)
- 7560437- [Nucleic acid compositions for eliciting an immune response against telomerase reverse transcriptase](#)
- 7560438- [Genetic inhibition by double-stranded RNA](#)
- 7563581- [Methods for detecting and localizing DNA mutations by extension of differentially fragmented DNA](#)
- 7563583- [Heregulin variants](#)
- 7563584- [Methods and compositions for detecting the activation state of multiple proteins in single cells](#)
- 7563598- [Detection of truncation mutations by mass spectrometry](#)
- 7566533- [Clinically intelligent diagnostic devices and methods](#)
- 7566536- [WNT-regulated cytokine-like polypeptide and nucleic acids encoding same](#)
- 7584058- [Genetic diagnosis using multiple sequence variant analysis](#)
- 7585622- [Increasing the proliferative capacity of cells using telomerase reverse transcriptase](#)
- 7585673- [.gamma.-heregulin](#)
- 7608451- [Gene regulation in transgenic animals using a transposon-based vector](#)
- 7608635- [Pyrazole compounds that modulate HSP90 activity](#)
- 7608704- [Secreted proteins](#)
- 7609061- [Demagnetized implant for magnetic resonance imaging](#)
- 7611532- [Coated implantable medical device](#)

- 7611533- [Coated implantable medical device](#)
- 7611704- [Compositions and methods for treating viral infections using antibodies and immunoconjugates to aminophospholipids](#)
- 7611879- [27877, 18080, 14081, 32140, 50352, 16658, 14223, 16002, 50566, 65552 and 65577 molecules and uses therefor](#)
- 7612039- [Method of cell growth inhibition with agnoprotein](#)
- 7612080- [GTPase inhibitors and use thereof for controlling platelet hyperactivity](#)
- 7608392- [Diagnostic assay for measuring a cell mediated immune response](#)
- 7608257- [Sensitization of chemotherapeutic agent resistant neoplastic cells with a virus](#)
- 7585864- [Farnesyl protein transferase inhibitors and their use to treat cancer](#)
- 7592010- [Albumin fusion proteins](#)
- 7592422- [Modified plasminogen activator inhibitor type-1 and methods based thereon](#)
- 7592429- [Sclerostin-binding antibody](#)
- 7593818- [Genetic diagnosis using multiple sequence variant analysis](#)
- 7595315- [Morpholine derivatives as norepinephrine reuptake inhibitors](#)
- 7598060- [Rapid analysis of variations in a genome](#)
- 7598232- [Amino-substituted \(E\)-2,6-dialkoxystyryl 4-substituted-benzylsulfones for treating proliferative disorders](#)
- 7598383- [Heterocyclic inhibitors of MEK and methods of use thereof](#)
- 7605175- [Inhibitors of cyclin-dependent kinases, compositions and uses related thereto](#)
- 7615223- [Selected immunoconjugates for binding to aminophospholipids](#)

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

